(Q38097423)

English

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

scientific article published on 08 April 2013

Statements

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (English)
Michail Lichinitser
Vladimir Semiglazov

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit